The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation
- PMID: 2402772
- DOI: 10.1046/j.1537-2995.1990.30790385516.x
The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation
Abstract
The treatment of plasma with organic solvent/detergent mixtures at the time of plasma collection or pooling could reduce the exposure of technical staff to infectious viruses and enhance the viral safety of the final product. Treatment of plasma for 4 hours with 2-percent tri(n-butyl)phosphate (TNBP) at 37 degrees C, with 1-percent TNBP and 1-percent polyoxyethylensorbitan monooleate (Tween 80) at 30 degrees C, or with 1-percent TNBP and 1-percent polyoxyethylene ethers, (Triton X-45) at 30 degrees C resulted in the rapid and complete inactivation of greater than or equal to 10(4) tissue culture-infectious doses (TCID50) of vesicular stomatitis and Sindbis viruses, which are used as surrogates. Treatment of plasma with TNBP and TNBP and Tween-80 was shown to inactivate greater than or equal to 10(4) TCID50 of human immunodeficiency virus. TNBP treatment of plasma contaminated with 10(6) chimpanzee-infectious doses (CID50) of hepatitis B virus and 10(5) CID50 of non-A,non-B hepatitis virus prevented the transmission of hepatitis to chimpanzees. Immediately after treatment of plasma with 2-percent TNBP, the recovery of factors VIII, IX, and V and antithrombin III was 80, 90, 40, and 100 percent, respectively. Recovery of all factors was greater than or equal to 90 percent after treatment with TNBP and detergent mixtures. Treated plasma was fractionated by standard techniques into antihemophilic factor and prothrombin complex concentrates, immune globulin, and albumin. Prior treatment with TNBP or TNBP and detergent did not affect the separations of desired proteins. Therefore, it appears possible to inactivate viruses in plasma before the execution of standard fractionation procedures.(ABSTRACT TRUNCATED AT 250 WORDS)
Comment in
-
Potential accumulation of tri(n-butyl)phosphate in solvent-detergent virus-inactivated plasma products.Transfusion. 1991 Nov-Dec;31(9):871. doi: 10.1046/j.1537-2995.1991.31992094678.x. Transfusion. 1991. PMID: 1755094 No abstract available.
Similar articles
-
Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.Lancet. 1986 Mar 29;1(8483):706-10. doi: 10.1016/s0140-6736(86)91101-3. Lancet. 1986. PMID: 2870224
-
Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations.Transfusion. 1985 Nov-Dec;25(6):516-22. doi: 10.1046/j.1537-2995.1985.25686071422.x. Transfusion. 1985. PMID: 3934801
-
Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma.Blood. 1992 Feb 1;79(3):826-31. Blood. 1992. PMID: 1310064
-
Viral safety of solvent-detergent treated blood products.Dev Biol Stand. 1993;81:147-61. Dev Biol Stand. 1993. PMID: 8174797 Review.
-
[Virus inactivated plasma].Infusionsther Transfusionsmed. 1994 Aug;21 Suppl 1:73-6. Infusionsther Transfusionsmed. 1994. PMID: 8000259 Review. German.
Cited by
-
Blood protein derivative viral safety: observations and analysis.Yale J Biol Med. 1990 Sep-Oct;63(5):361-9. Yale J Biol Med. 1990. PMID: 1963504 Free PMC article. Review.
-
Use of humanised rat basophilic leukaemia cell line RS-ATL8 for the assessment of allergenicity of Schistosoma mansoni proteins.PLoS Negl Trop Dis. 2014 Sep 25;8(9):e3124. doi: 10.1371/journal.pntd.0003124. eCollection 2014 Sep. PLoS Negl Trop Dis. 2014. PMID: 25254513 Free PMC article.
-
Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV-2).Viruses. 2022 Oct 31;14(11):2419. doi: 10.3390/v14112419. Viruses. 2022. PMID: 36366517 Free PMC article.
-
Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases.J Clin Immunol. 2004 May;24(3):309-14. doi: 10.1023/B:JOCI.0000025453.23817.3f. J Clin Immunol. 2004. PMID: 15114062 Clinical Trial.
-
Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.Int J Hematol. 2009 Nov;90(4):446-454. doi: 10.1007/s12185-009-0435-x. Epub 2009 Nov 3. Int J Hematol. 2009. PMID: 19882376 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources